President Trump to pick MD Anderson Cancer Center doctor as next FDA commish: WSJ

White House
President Donald Trump is set to make his pick for FDA commissioner next week, according to a Wall Street Journal report. (Pixabay)

President Donald Trump is set to pick oncologist Stephen Hahn, currently chief medical executive at MD Anderson Cancer Center in Houston, as the next FDA commissioner, forgoing current leader Ned Sharpless.

This is according to The Wall Street Journal, citing sources “familiar with the matter.”

The sources told the WSJ the pick is expected to be confirmed next week, in time for the end of Sharpless’ acting tenure, which is up Nov. 1. The Senate would need to confirm a new commissioner.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

Sharpless took over on a temporary basis after media and biopharma favorite Scott Gottlieb unexpectedly left in the spring, later to take on a series of healthcare company roles.

Sharpless, formerly director of the National Cancer Institute, is still seen as a front-runner, but Hahn, formerly chairman of radiation oncology at the University of Pennsylvania School of Medicine, has been edging into the race in recent weeks, according to reports.

RELATED: In the race for permanent FDA chief, Sharpless is a top pick. But he's not alone

The FDA has been undergoing something of a cultural shift in recent years, with a focus on speedy reviews but arguably at the expensive of a slower, more considered approach to drug approvals.

Some greenlights, such as for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) therapy three years ago, saw internal and external wrangling at the regulator about whether the bar was being lowered. There are also whispers as to how political the FDA’s rejection of Sarepta’s second attempted DMD approval was, and as a backlash to its first.

RELATED: FDA surprises Sarepta by spurning its 2nd Duchenne drug

With Trump being elected in 2016 and his mandate of slashing regulation in general to cut costs and boost efficacy, concerns deepened that his pick(s) may lower that bar further.

A big test of this is on the horizon: namely, with Biogen’s once failed and canned Alzheimer’s disease drug aducanumab, now resurrected in time for Halloween and set to spook more than a few FDA insiders.

Biogen, working some data magic/dredging operation, found that their drug may actually work in some Alzheimer’s patients, though skepticism is sky-high from some analysts and bio-Twitterati (though investors, not so much).

Biogen had it said spoken with the FDA, which appeared happy for it to attempt to file the drug. Anything could happen: a refuse to file notice, a demand for another phase 3 trial, a hostile AdComm, even a flat-out no. Whatever the decision and path, this will be a litmus test for any commissioner as well as the FDA itself.

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.